International Stem Cell Corporation revenue by segment ISCO

Annual Quarterly

International Stem Cell Corporation splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Biomedical Market at $8.5 million, 93% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Media at $5.8 million, 64% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	10	9	9	8	8	7	7	9	11	7	7
Operating segments
Biomedical Market	9 +4.1% share 93.5%	9 +2.6% share 93.4%	8 +20.7% share 91.2%	7 -3.7% share 88.1%	7 +20.1% share 87.2%	6 +6.1% share 82.7%	6 share 78.5%	—	—	—	—
Anti Aging Skincare Market	1 -6.1% share 6.5%	1 -24.8% share 6.6%	1 -13.9% share 8.8%	1 -12.0% share 11.9%	1 -15.4% share 12.8%	1 -19.2% share 17.3%	2 share 21.5%	—	—	—	—
Sales mix
Media	6 +8.4% share 65.7%	6 -2.5% share 63.8%	6 +25.5% share 65.5%	5 -8.6% share 60.9%	5 +13.1% share 63.4%	5 +5.5% share 63.9%	4 share 61.0%	—	—	—	—
Cells	3 -4.7% share 27.8%	3 +15.4% share 29.6%	2 +10.0% share 25.7%	2 +9.4% share 27.3%	2 +44.1% share 23.7%	1 +9.8% share 18.8%	1 share 17.2%	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ISCO (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: San Diego, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1355790
Former names: BTHC III INC. (until Jan 19, 2007)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.